Federal Trade Commission sues largest drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the companies of artificially inflating insulin list prices that resulted in patients paying more for the medications.
Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...
The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...
The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the ...
The original developers of insulin deemed it unethical to profit off the life-saving therapeutic, selling the patent to the University of Toronto for just $1 in 1923. For the last 25 years, PBMs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback